Anemia in End-Stage Renal Disease (ESRD)
Understanding Anemia in End-Stage Renal Disease (ESRD) is crucial for healthcare professionals. This resource provides information on Anemia in CKD Stage 5, also known as Renal Anemia, including diagnosis, clinical documentation, and medical coding for ICD-10 and SNOMED CT. Learn about the connection between ESRD and anemia, treatment options, and best practices for accurate medical coding and documentation in a clinical setting.
Decreased red blood cell count caused by reduced erythropoietin production in kidney failure.
Fatigue, weakness, shortness of breath, pale skin, dizziness, and rapid heart rate.
Dialysis clinics, nephrology units, and primary care offices managing chronic kidney disease.
ICD-10 Code Families
Complete code families applicable to D63.1
When to use each related code
| Description | When to use |
|---|---|
| Low red blood cell count due to kidney failure. | Use for anemia specifically caused by ESRD/CKD Stage 5. Consider iron deficiency anemia if present. |
| Low iron levels causing anemia. | Use when low iron is the primary cause of anemia, regardless of kidney function. Often coexists with renal anemia. |
| Anemia from chronic disease other than kidney failure. | Use when anemia is linked to chronic inflammation or infections. Exclude renal causes first. |
Best-practice checklist
- ✓Document CKD stage 5 diagnosis.
- ✓Specify anemia type (e.g., normocytic, normochromic).
- ✓Hemoglobin/hematocrit levels required.
- ✓Iron studies documentation needed.
- ✓ESRD-related anemia symptoms documented.
Common pitfalls to avoid
Coding anemia in ESRD without specifying the type (e.g., iron deficiency, aplastic) leads to inaccurate severity reflection and reimbursement.
Lack of explicit CKD stage 5 documentation may cause downcoding to a less severe CKD stage, impacting reimbursement and quality metrics.
Coding for erythropoiesis-stimulating agents (ESAs) requires documented justification of medical necessity to ensure compliance and avoid denials.
Best-practice tips
- 01Document CKD stage, Hgb levels, iron studies for accurate coding (ICD-10-CM N18.3, Z99.2).
- 02CDI: Query physician for anemia cause and treatment details for complete documentation.
- 03Optimize ESRD anemia management with ESA therapy, iron supplementation per KDOQI guidelines.
- 04Monitor iron status, transferrin saturation, ferritin regularly for compliance and safety.
- 05Regular Hgb monitoring and ESA dose adjustment minimize risks and optimize outcomes.
Step-by-step checklist
- 1
Confirm ESRD diagnosis (ICD-10 N18.5, N18.6) documented.
- 2
Check hemoglobin level: <10 g/dL indicates anemia.
- 3
Evaluate iron studies (ferritin, transferrin saturation).
- 4
Consider other anemia causes (e.g., blood loss, nutritional).
Ready-to-paste narrative
Patient presents with symptoms consistent with anemia in end-stage renal disease (ESRD), also known as renal anemia or anemia in chronic kidney disease (CKD) stage 5. The patient's glomerular filtration rate (GFR) confirms stage 5 CKD, and laboratory results demonstrate a decreased hemoglobin level below the threshold for diagnosis of renal anemia. Symptoms reported include fatigue, weakness, shortness of breath, and decreased exercise tolerance. These symptoms are impacting the patient's quality of life and functional status. Physical examination reveals pallor. Differential diagnosis includes iron deficiency anemia, anemia of chronic inflammation, and other causes of anemia. Iron studies, including ferritin, transferrin saturation, and total iron binding capacity, have been ordered to evaluate for iron deficiency. C-reactive protein (CRP) has been assessed to evaluate for inflammation. Erythropoietin deficiency, secondary to decreased kidney function, is considered the primary etiology of the anemia. Treatment plan includes erythropoiesis-stimulating agents (ESAs) and iron supplementation if indicated by iron studies. Patient education regarding anemia management in ESRD, including the importance of medication adherence and regular monitoring of hemoglobin levels, has been provided. Follow-up appointment scheduled to monitor response to therapy and adjust treatment as needed. ICD-10 coding will include N18.5 for CKD stage 5 and D63.81 for anemia in CKD. Monitoring and documentation will continue to assess the efficacy of the treatment and any potential adverse effects.
Common questions and answers
What are the best evidence-based strategies for managing anemia resistance to erythropoiesis-stimulating agents (ESAs) in end-stage renal disease patients?+
Anemia resistance to ESAs is a significant challenge in ESRD management. Evidence-based strategies include optimizing iron therapy by ensuring adequate iron stores and evaluating for functional iron deficiency, considering the use of intravenous iron administration if necessary. Explore how adjusting ESA dosing and frequency, based on individual patient response and hemoglobin targets, can improve outcomes. Additionally, identifying and addressing underlying causes of ESA resistance, such as inflammation, infection, malnutrition, or blood loss, is crucial. Consider implementing a multidisciplinary approach involving nephrologists, dietitians, and other specialists to optimize patient care. Learn more about the role of newer agents like hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in managing ESA-resistant anemia.
How do I differentiate between iron deficiency anemia and anemia of chronic inflammation in patients with end-stage renal disease undergoing dialysis?+
Differentiating between iron deficiency anemia and anemia of chronic inflammation in ESRD patients on dialysis can be complex due to overlapping features. While both conditions present with low hemoglobin, key distinguishing factors include assessing iron indices like ferritin, transferrin saturation, and total iron-binding capacity. In iron deficiency anemia, ferritin and transferrin saturation are typically low, while TIBC is elevated. In contrast, anemia of chronic inflammation often shows elevated or normal ferritin levels due to its role as an acute-phase reactant, along with low transferrin saturation and normal or slightly low TIBC. Furthermore, inflammatory markers like C-reactive protein (CRP) and interleukin-6 (IL-6) are often elevated in anemia of chronic inflammation. Consider implementing comprehensive laboratory evaluations to accurately diagnose and tailor appropriate treatment strategies. Explore how functional iron deficiency, where iron is present but not readily available for erythropoiesis, can further complicate the diagnosis and management of anemia in ESRD.
What are the potential cardiovascular complications of anemia in CKD stage 5, and how can they be mitigated?+
Anemia in CKD stage 5 significantly increases the risk of cardiovascular complications, including left ventricular hypertrophy, heart failure, and ischemic heart disease. The reduced oxygen-carrying capacity of the blood due to anemia leads to increased cardiac workload and compensatory mechanisms that contribute to these complications. Effective management of anemia through strategies like erythropoiesis-stimulating agents (ESAs), iron supplementation, and addressing underlying causes of anemia can help mitigate these risks. Learn more about the importance of maintaining hemoglobin targets within the recommended range to balance the benefits of anemia correction with potential adverse effects of ESA therapy. Consider implementing regular cardiovascular monitoring in CKD stage 5 patients, including echocardiography and assessment of cardiac biomarkers, to detect and manage cardiovascular complications early.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.